Trausurethral plasmakinetic electrovaporization therapy for high risk patients with benign prostate hyperplasia (report of 72 cases)

Abstract

Objective To evaluate the safety and efficacy of transurethral bipolar plasmakinetie eleetrovaporization (TUBVP) for the treatment of high risk patients with benign prostate hyperplasia. Methods The clinical experiences of transurethral plasmakinetie electrovaporization (TUBVP) treatment in 72 eases of benign prostate hyperplasia during Mar 2004 to Jan 2008 were analyzed. Information in operation and postoperative complications and curative effect were observed. Results Total of 72 patients underwent TUBVP safely. The operating time was from 36 to 82 minutes, averaged 48 rain. The specimen weight was 48 - 106 g, with more than 60 g in 38 eases. The mean blood loss was 70 ml (60 -100 ml). Urinary tract irritation symptom were found in 17 patients with 1 week postoperatively. No postoperative complications such as transurethral resection syndrome, bleeding, intestinal fistula and urinary incontinence occurred. With follow up of 4 -6 months, all patients had fluent urination. Average Maximal flow rate(Qmax) was 18.5 ml/s. The International Prostate Symptom Scores(IPSS) were decreased to 6.7 ± 1.4. Quality of Life(QOL) decreased to 1.8 ±0.4. Conclusions With high effectiveness, safety, short hospital stay and less'complications, TUBVP is a safe and effective therapy to high risk patients with benign prostate hyperplasia. Key words: Prostate hyperplasia; High risk; Bipolar plasmakinetic electrovaporization therapy; Curative effect